Biomarkers of disease are assuming an ever increasing role in the discovery and development of drugs. ICON has long recognised their importance in all phases of the development process and has built up significant expertise in biomarker development and analysis. Working closely with sponsor, our global laboratory groups (Bioanalytical, Central and Imaging) and our Clinical Pharmacodynamics team lead the industry in biomarker research utilising the latest scientific innovation and state-of-the-art development platforms. ICON’s Imaging Core Laboratory is also an industry leader in the provision of imaging biomarkers that support drug development.